Last Updated on October 15, 2024 by The Health Master
Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of Hyderabad based Granules India Ltd. located in Chantilly, Virginia, US, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA).
“We are glad to have completed yet another audit after successfully addressing minor observations.
This is the sixth successful USFDA audit for this facility,” Priyanka Chigurupati, Executive Director, GPI, said in a release on Monday.
The GPI facility was inspected by the US FDA during January 24-28, 2022, for two of its product applications filed.
There were three minor observations during the inspection and GPI had addressed the observations in the stipulated time period.
USFDA gives tentative nod to Alembic for Macitentan Tablets 10 mg
Govt releases draft National Medical Device Policy 2022
Deadline extended for proposals under PLI scheme for Bulk Drugs
USFDA gives final nod to Zydus for Colestipol Hydrochloride tablets
Orders to close these 5 Pharmaceutical units
USFDA inspections back in full swing for Pharma Companies
Drug recall: Macleods recalls products for these manufacturing issues
NITI Aayog to expand ‘Medicines from the Sky’ project
Make Pharma Companies liable for bribing doctors: PIL
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
